ezAccounting Software Cuts Workload in Half for Employers with the New Add-On Feature to Efile the 1st Quarter 941 Form
The innovative IRS authorized 941 efile add-on feature for ezAccounting will eradicate the filing process for businesses and Human Resources. REDMOND, Wash., March... Read more.
Cleary Gottlieb Adds Premier Five-Partner Intellectual Property Litigation Team, Solidifying “Bet the Company” Capabilities
NEW YORK, March 31, 2025 /PRNewswire/ — Cleary Gottlieb announced today that a team of top-tier IP litigation lawyers has joined the firm as partners across... Read more.
Curis Provides Fourth Quarter 2024 Business Update
FDA and EMA discussions completed to support a potential accelerated approval path in both US and EU Orphan Drug Designation for PCNSL granted in both US and EU... Read more.
Nearly a Third of Generative AI Users Look to RAG to Support Information Handling According to New Survey
Security and quality of data indicate need for better data governance – joins, insufficient skills, and lack of context awareness as are the greatest risks... Read more.
Wipfli announces Rebekah Gardner as new chief growth officer
Transformational leader to drive strategic growth and innovation MILWAUKEE, March 31, 2025 /PRNewswire/ — Wipfli, a top 25 advisory and accounting firm, is... Read more.
A New Era of Unlocking Answers & Hope
Turning Point with David Jeremiah Unveils Prophecy Explained a Groundbreaking New Website Dedicated to Biblical Prophecy SAN DIEGO, Calif., March 31, 2025 /PRNewswire/... Read more.
Study Examines Effect of App Crashes on Consumer Engagement
Researchers Suggest Developers Release Updates Cautiously, Target Resilient Users and Take Responsibility for Crashes to Maintain Trust COLLEGE PARK, Md., March... Read more.
New ownership, new name – composite resins by Alta Performance Materials
KPS Capital Partners & INEOS Enterprises close sale of INEOS Composites INEOS Composites now Alta Performance Materials New chapter for leading global manufacturer... Read more.
Transcend Therapeutics Announces Primary Endpoint Met in IMPACT-1 Phase 2 Study of TSND-201 in PTSD
Primary endpoint met, with TSND-201 demonstrating statistically significant placebo-adjusted CAPS-5 improvement of -9.64 points on Day 64 (p = 0.011) TSND-201 demonstrated... Read more.
Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil
Kazia to receive USD $1 million from Vivesto for the intellectual property and trademark assets rights to the oncology drug candidate, Cantrixil SYDNEY, March 31,... Read more.